Magnite heads into the final stretch of 2026 with shorts retreating, analyst targets rising, and a 16% earnings pop in August still fresh in the market's memory.
The short positioning story is one of steady unwinding. Short interest has fallen roughly 6.5% over the past month, now running at 7.4% of the free float — down from above 8% in mid-August. The trend is unambiguous: bears have been covering for six consecutive weeks. Borrow conditions reinforce that picture. Cost to borrow has dropped 10% this week to just 0.37%, the lowest reading of the past month. Availability is exceptionally loose at 1,156% — meaning there are more than eleven times as many shares available to lend as are currently borrowed — well above even the 52-week tightest reading of 395%. Anyone who wants to get short faces no friction whatsoever in the lending market. Options sentiment is broadly neutral, with the put/call ratio at 0.91, slightly above its 20-day average of 0.87 but only 0.4 standard deviations away — nowhere near the defensive posturing seen in late August when the ratio pushed above 1.08.
The Street has turned meaningfully more constructive since the August earnings beat. B. Riley raised its target to $30 this week, and Needham did the same earlier in September, lifting its view from $25. RBC moved its target from $20 to $27 after the August print, and Benchmark went to $33. The pattern is consistent: bulls are lifting their numbers while maintaining positive ratings, and the consensus target now sits around $28.80 — implying roughly 16% upside from Tuesday's close of $24.80. The one holdout is Wells Fargo, which kept an Equal-Weight and nudged its target only to $22, below the current price. EV/EBITDA sits near 11.9x, a modest compression relative to 30 days ago, while the price-to-earnings multiple has drifted to about 20x — not demanding for a company with CTV exposure growing at this pace. Factor scores are mixed: the short-score rank at 24 and days-to-cover rank at 32 both sit in the lower half of the universe, consistent with a stock where bears are in retreat.
The institutional ownership picture adds texture. BlackRock has been the most active large buyer, adding over one million shares to reach 8.86% of the company. Fidelity (FMR LLC) added more than three million shares to hit 5.4%. These are material accumulation moves, not passive drift. The activist register is clean — no Schedule 13D filers, only passive 13G holders — though one notable shift is worth flagging: The Vanguard Group's consolidated entity reported reducing its aggregate stake from 10.3% to effectively zero in March, while two successor Vanguard entities filed fresh 13G disclosures in April at 5.4% and 5.0% respectively. This appears to reflect a restructuring of how Vanguard reports rather than genuine liquidation, but the 13D/G register is as-last-disclosed and positions around the 5% threshold can change without further filings.
Insider activity is the one cautionary note in an otherwise improving picture. Net selling totals roughly $19 million over the past 90 days, with sales spread across directors and the Chief Legal Officer. Most are under pre-arranged 10b5-1 plans — mechanically scheduled, not discretionary reactions to price. The exception is a mid-September sale by director Robert Spillane, which was not covered by a 10b5-1 plan and followed an option exercise. A single non-plan sale from a director carries more informational weight than a scheduled programme, though at roughly $246,000 it is not large enough on its own to shift the narrative.
The next earnings date is November 4. The August print produced a 16.6% one-day move and the gain held through the five-day window — the most dramatic single-session reaction the company has generated in recent quarters. With shorts still at 7.4% of the float and analyst targets clustering well above the current price, the setup into that release is the tension worth watching.
See the live data behind this article on ORTEX.
Open MGNI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
